arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Adicet Bio, Inc.

ACET
$8.06 ▲ +0.07 (+0.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adicet Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $86.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -15.4%
FCF / Share $-2.00
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-20.24M
↑ +28.2%
FCF / Share Free cash flow per share
$-2.00
↓ -578.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Financial Health
2
Cash Quality
56

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters